Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2025Expert Review of Clinical Immunology

Immune pathways, current and potential therapies in Mycosis Fungoides and sezary syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

FBFriyana BhabhaCWCarrie Van Der WeydenJCJoshua Casan

Discussion

Loading...

Member takes

Overview

This review examines immunotherapies and targeted therapies for mycosis fungoides and Sézary syndrome, highlighting current clinical outcomes and potential innovations.

Key Points

  • Mycosis fungoides is the most common form of cutaneous T cell lymphoma, while Sézary syndrome represents a more aggressive subtype.
  • Large cell transformation is rare in mycosis fungoides and associated with a poor prognosis.
  • Accelerating understanding of the tumor microenvironment is critical to developing targeted therapies for patients.
  • Emerging immunotherapies and biologic agents promise improved clinical outcomes for advanced cutaneous T cell lymphomas.

Cite This Study

Bhabha et al. (2025) studied this question.

synapsesocial.com/papers/689a02b6e6551bb0af8cc2b1https://doi.org/10.1080/1744666x.2025.2533367
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unraveling the role of chemokines in cutaneous T-cell lymphoma: expression levels at different stages2025 · 7 citations
  2. 2Skin-Directed Therapies in Mycosis Fungoides: An Update2025
  3. 3Genomic landscape of mycosis fungoides2025
  4. 4Mycosis Fungoides: a review2025 · 11 citations
  5. 5Clinical and Prognostic Features of Erythrodermic Cutaneous T-Cell Lymphoma: A Retrospective Study of 35 Patients2025